These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000329-31 Continuous fluorouracil plus mitomycin C versus mitomycin C plus Cisplatin as chemotherapy combination in combined radiochemotherapy for locally advanced anal cancer. A phase II-III study 2008-10-03 due-trials
Reported results 2004-000654-23 Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group 2011-03-30 due-trials
Reported results 2004-000731-28 A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer 2009-08-25 due-trials
Reported results Terminated 2004-001108-11 A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-based ... 2021-01-13 due-trials
Reported results 2004-001331-36 A randomized phase III study of follow up with or without adjuvant Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer 2009-12-02 due-trials
Reported results 2004-001332-23 Phase II Study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC. 2005-11-04 due-trials
Reported results 2004-001558-10 BEACOPP (4 ciclos escalado + 4 ciclos basal) vs ABDV (8 ciclos) en el linfoma de Hodgkin en estadios III-IV. 2012-08-31 due-trials
Reported results 2004-001746-32 Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy 2010-06-25 due-trials
Reported results 2004-001810-16 Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu... 2017-07-12 due-trials
Ongoing 2004-001858-90 Randomised Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer : 6-month Infusional 5FU-CPT11 (+/- Folinic Acid) versus Observation. Determination of Biologic Predictive and Response... not-yet-due
Reported results 2004-001937-40 Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma 2010-05-31 due-trials
Reported results 2004-002094-23 Estudio aleatorizado de fase II de docetaxel (Taxotere) y oblimersén (oligonucleótido antisentido dirigido frente a bcl-2) vs. Taxotere solo en pacientes con cáncer de próstata refractario a la hormon... 2006-09-29 due-trials
Reported results 2004-002113-36 Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma 2012-07-05 due-trials
Reported results 2004-002245-12 Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group. 2011-06-08 due-trials
Reported results 2004-002538-20 Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFibroS... 2008-12-18 due-trials
Reported results 2004-002714-11 Estudio de fase III para evaluar la quimioterapia primaria con temozolomida frente a la radioterapia en pacientes con gliomas de bajo grado, con estratificación por pérdida del 1p 2014-05-14 due-trials
Reported results 2004-002944-90 A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin CASP in the Firstline Treatment of probable and proven Invasive Aspergillosis IA in Patients with Hematolo... 2008-07-01 due-trials
Reported results 2004-003701-24 A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES. 2010-05-31 due-trials
Reported results 2004-003728-36 PHASE II CLINICAL TRIAL WITH CAELYX MONO-CHEMOTHERAPY IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES STAGE IIb, IVa AND IVb WITH OR WITHOUT PREVIOUS CHEMOTHERAPY. 2010-06-25 due-trials
Reported results 2004-003896-35 Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM 2008-09-15 due-trials
Reported results 2004-004273-28 A phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with malignant pleural mesothelioma. 2008-12-02 due-trials
Reported results 2004-004333-34 A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and S... 2012-10-31 due-trials
Completed, but no date, and reported results 2004-004356-39 Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial... bad-data
Listed as ongoing, but also has a completion date 2004-004456-39 A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca... 2012-06-01 bad-data
Reported results 2005-000679-16 Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia 2006-12-14 due-trials
Reported results 2005-000933-39 Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head can... 2011-04-29 due-trials
Listed as ongoing, but also has a completion date 2005-002625-31 MINDACT (El uso de microarray en la enfermedad con ganglios negativos y de 1 a 3 ganglios positivos puede evitar la quimioterapia). Estudio prospectivo, aleatorizado que compara la firma de expresión ... 2020-02-26 bad-data
Reported results 2005-002765-37 The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's ly... 2015-01-09 due-trials
Reported results 2005-002825-29 Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment i... 2011-09-28 due-trials
Reported results 2005-002830-36 Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10 % blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic... 2008-06-04 due-trials
Reported results 2005-003822-25 Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC) 2019-02-19 due-trials
Reported results 2005-005177-29 Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma 2016-12-01 due-trials
Reported results 2006-000009-51 Phase II study of Bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma 2012-01-20 due-trials
Reported results 2006-000864-94 A Phase I-II Study of Lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer 2015-04-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001533-17 Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. 2018-08-02 bad-data
Reported results 2006-001659-37 Phase II Study of ZK 219 477 in patients with recurrent glioblastoma 2008-06-16 due-trials
Reported results 2006-002485-19 Estudio de Fase II de sunitinib (SU011248) en pacientes con cáncer de pulmón de células pequeñas que nunca han recibido quimioterapia (enfermedad extensiva) o que presentan una recaída ?sensible? 2012-08-27 due-trials
Exempt, with results 2006-002667-33 Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx... not-yet-due
Reported results 2006-002772-17 Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage postoperative external radiotherapy alone in... 2014-01-05 due-trials
Reported results 2006-004189-14 Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies 2011-04-01 due-trials
Exempt, with results 2006-004912-28 Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia ... 2014-07-24 not-yet-due
Reported results 2006-006532-21 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) 2015-12-31 due-trials
Reported results Terminated 2007-002257-23 A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate. 2011-03-11 due-trials
Reported results 2008-001949-26 A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS 2016-09-04 due-trials
Reported results 2008-003003-31 Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a random... 2014-03-03 due-trials
Reported results 2008-003396-52 Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer. 2019-11-29 due-trials
Reported results 2008-006180-36 Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk o... 2011-07-18 due-trials
Ongoing 2008-007295-14 Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. not-yet-due
Reported results 2009-010273-20 Adjuvant peginterferon alda-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. Pegint... 2020-07-11 due-trials
Reported results 2009-011020-65 A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma. 2014-06-03 due-trials
Reported results 2009-011580-36 Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) a... 2014-03-04 due-trials
Reported results 2009-014889-26 TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissu... 2017-04-17 due-trials
Reported results 2009-017422-39 Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. 2017-09-27 due-trials
Reported results 2009-017485-23 TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial) 2018-08-22 due-trials
Reported results 2010-018566-23 Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study. 2015-06-26 due-trials
Reported results 2010-019238-29 Ensayo de fase II con asignación aleatoria que evalúa la eficacia de FOLFOX solo, FOLFOX más bevacizumab y FOLFOX más panitumumab como tratamiento perioperatorio en pacientes con metástasis hepática e... 2018-07-25 due-trials
Reported results 2010-020814-27 Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase ... 2019-04-04 due-trials
Reported results 2010-023218-30 Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma 2018-02-10 due-trials
Reported results 2010-024077-39 Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal ... 2020-07-13 due-trials
Ongoing 2011-000618-20 A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA Essai de Phase I... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-001988-52 Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET. 2022-10-30 bad-data
Reported results 2011-002947-83 Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatri... 2016-11-22 due-trials
Reported results Terminated 2011-005473-22 Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group. 2014-03-25 due-trials
Reported results 2011-005820-17 Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study. 2016-04-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-006342-32 Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while ... 2022-08-11 bad-data
Reported results Terminated 2012-002122-67 Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. Ensayo ... 2014-06-30 due-trials
Reported results Terminated 2012-002852-17 A PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) V. OBSERVATION FOR UTERUS-LIMITED, HIGH GRADE UTERINE LEIOMYOSARCOMA 2017-03-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003672-39 Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma 2021-02-02 bad-data
Reported results 2012-004295-19 A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line ther... 2019-08-28 due-trials
Listed as ongoing, but also has a completion date 2013-000314-38 A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressi... 2024-02-16 bad-data
Listed as ongoing, but also has a completion date 2013-000762-11 A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubic... 2024-01-15 bad-data
Reported results 2013-002441-12 A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treat... 2019-09-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-000501-13 Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib 2021-02-23 bad-data
Listed as ongoing, but also has a completion date 2014-000722-38 INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL 2024-09-30 bad-data
Completed, reported early 2014-001486-27 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS St... 2024-03-29 not-yet-due
Other 2014-001787-36 A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastat... not-yet-due
Reported results 2014-002446-47 Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group. 2019-01-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-003090-42 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer 2022-06-22 bad-data
Ongoing 2014-003930-17 A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED... not-yet-due
Listed as ongoing, but also has a completion date 2015-001298-42 A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) 2024-05-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2015-004601-17 A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian ... 2022-02-16 bad-data
Ongoing 2015-005098-19 Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized ... not-yet-due
Other 2015-005504-28 Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2016-000521-38 Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group 2023-10-12 bad-data
Ongoing 2016-001834-82 APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients not-yet-due
Listed as ongoing, but also has a completion date and reported results 2016-002093-12 A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastatic ... 2021-05-13 bad-data
Reported results 2016-003535-38 Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma 2020-06-05 due-trials
Ongoing 2016-004334-17 A phase 2 Randomized Open-Label Study of Oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer Estudio en fase II, aleatoriz... not-yet-due
Listed as ongoing, but also has a completion date 2017-000086-74 A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM" 2024-11-12 bad-data
Other 2017-000498-35 Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study not-yet-due
Reported results 2017-001375-22 EORTC ILOC study: Phase II of immunotherapy plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with colorectal cancer liver metastases EORTC ILOC-Studie: Eine Phase-II-Studie ... 2022-02-22 due-trials
Ongoing 2017-002887-42 Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectabl... not-yet-due
Other 2017-003323-30 Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2017-003680-35 Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT) 2022-08-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003908-50 A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastom... 2022-08-22 bad-data
Reported results Terminated 2018-000053-53 Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL) 2020-11-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-000406-36 Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VES... 2023-08-11 bad-data
Reported results Terminated 2018-000899-15 Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study 2020-07-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-002096-17 Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE" 2021-03-25 bad-data
Ongoing, reported early 2018-002553-30 A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-003539-31 IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study 2021-12-29 bad-data
Reported results Terminated 2018-003902-14 DKN-01/atezolizumab as second line treatment of biliarY tract cancer and in combiNAtion or not with paclitaxel as second line treatMent of esophagogastrIC cancer: a multi-center Phase II Trial 2020-01-27 due-trials
Other 2019-000308-13 Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and D... not-yet-due
Other 2019-003543-30 A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma not-yet-due
Ongoing 2019-003862-41 Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor not-yet-due
Other 2019-004566-17 Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma not-yet-due
Reported results Terminated 2019-004891-20 Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL) 2023-06-02 due-trials
Listed as ongoing, but also has a completion date 2020-003063-26 PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma PersoMed-I : Thérapie adaptée au risque personnalisée chez les patients post-pubertaires... 2024-03-14 bad-data
Not reported Terminated 2020-005429-10 Romiplostim for thrombocytopenia induced by lomustine at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study Romiplostim para tratar la t... 2022-12-19 due-trials
Completed, report not yet due 2021-000125-27 TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosp... 2023-11-26 not-yet-due
Listed as ongoing, but also has a completion date 2022-003594-33 Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE) 2023-11-27 bad-data